PurposeFor protein expression of CYP2C19
|Item||Catalog #||Description||Quantity||Price (USD)|
|Plasmid||69606||Standard format: Plasmid sent in bacteria as agar stab||1||$85|
This material is available to academics and nonprofits only.
- Backbone size w/o insert (bp) 5500
Vector typeBacterial Expression
Growth in Bacteria
Bacterial Resistance(s)Ampicillin, 100 μg/mL
Copy numberHigh Copy
SpeciesH. sapiens (human)
Mutationdeletion of AA1-8 and mutation I331V
Entrez GeneCYP2C19 (a.k.a. CPCJ, CYP2C, CYPIIC17, CYPIIC19, P450C2C, P450IIC19)
- Cloning method Restriction Enzyme
- 5′ cloning site NdeI (not destroyed)
- 3′ cloning site HindIII (not destroyed)
- 5′ sequencing primer pCW-SEQ-fwd (5'ACATCGTATAACGTTACTGG-3')
- 3′ sequencing primer pCW-SEQ-rev (5'-CTTTCGTCTTCAAGCAGATCTG-3') (Common Sequencing Primers)
Terms and Licenses
- Not Available to Industry
- Zeocin® is an InvivoGen trademark.
Modification of CYP2C19 for bacterial expression as per Barnes et al. PNAS 88:5597, 1991 [PMID: 1829523]: First 8 amino acids of CYP2C cDNAs replaced with those of bovine 17α hydroxylase (MALLLAVF) to optimize bacterial expression.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
For your Materials & Methods section:CYP2C19 was a gift from Joyce Goldstein (Addgene plasmid # 69606 ; http://n2t.net/addgene:69606 ; RRID:Addgene_69606)